All releases

Feb 10, 2016

Verseon Corporation (“Verseon” or the “Company”)

Verseon to Present New Preclinical Results for Novel Class of Oral Anticoagulants at the 3rd International Conference on Heart & Brain

FREMONT, Calif.—Verseon Corporation (AIM: VSN) will present a poster featuring new data for several promising oral anticoagulant drug candidates on February 25th at the 3rd International Conference on Heart — Brain (ICHB) in Paris. Verseon's candidates represent a novel class of highly selective direct thrombin inhibitors (DTIs) with superior preclinical bleeding risk profiles when compared to those of the existing oral NOACs.

Verseon, a technology-based pharmaceutical company, uses its proprietary computational drug discovery platform to devise novel therapeutics for unmet medical needs. The Company's new class of potent, highly selective DTIs has demonstrated excellent results in preclinical efficacy studies and has pharmacokinetic properties suitable for oral dosing.

"The new results we are presenting at ICHB include data from an additional comprehensive preclinical thrombosis model that further confirms the efficacy of Verseon's drug candidates," said Anirban Datta, Director of Discovery Biology at Verseon, "Our anticoagulants continue to show positive results as the program progresses."

- Ends -

For further information please contact

Verseon Corporation
Arthur Shmurun / Amy Thai +1 (510) 225 9000
Vane Percy & Roberts (Media Enquiries)
Simon Vane Percy +44 (0) 1737 821890
Abchurch Communications Ltd (PR Advisers)
Jamie Hooper / Alex Shaw +44 (0) 20 7398 7719

About Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. Verseon’s platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.


This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook,” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.